MedPath

Northwestern University Human Resources

Northwestern University Human Resources logo
🇺🇸United States
Ownership
Private
Established
1851-01-28
Employees
5K
Market Cap
-
Website
https://www.venturecat.northwestern.edu

Clinical Trials

1.3k

Active:91
Completed:771

Trial Phases

6 Phases

Early Phase 1:44
Phase 1:109
Phase 2:186
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1116 trials with phase data)• Click on a phase to view related trials

Not Applicable
648 (58.1%)
Phase 2
186 (16.7%)
Phase 1
109 (9.8%)
Phase 4
89 (8.0%)
Early Phase 1
44 (3.9%)
Phase 3
40 (3.6%)

Evaluating a Decreased Dose of Radiation Therapy to the Elective Neck for the Treatment of HPV-Related Oropharyngeal Cancer, ENLIGHT Trial

Not Applicable
Not yet recruiting
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
First Posted Date
2025-09-17
Last Posted Date
2025-09-17
Lead Sponsor
Northwestern University
Target Recruit Count
100
Registration Number
NCT07178301
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

Valproic AcId for Traumatic BRAin INjury Trial

Not Applicable
Not yet recruiting
Conditions
Moderate Traumatic Brain Injury (TBI)
Severe Traumatic Brain Injury
Interventions
Other: Standard of care treatment + normal saline
Drug: Valproic Acid (VPA)
First Posted Date
2025-09-10
Last Posted Date
2025-09-22
Lead Sponsor
Northwestern University
Target Recruit Count
432
Registration Number
NCT07166393
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

University of Arizona, Tucson, Arizona, United States

🇺🇸

University of Southern California, Los Angeles, California, United States

and more 5 locations

Personalized Theta-burst Stimulation for Long-lasting Changes in Approach/Avoidance Behavior

Not Applicable
Recruiting
Conditions
Approach/Avoidance Behavior
First Posted Date
2025-09-08
Last Posted Date
2025-09-08
Lead Sponsor
Northwestern University
Target Recruit Count
26
Registration Number
NCT07161505
Locations
🇺🇸

Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

REmote Physical ACtivity Intervention for High Blood Pressure Postpartum

Not Applicable
Not yet recruiting
Conditions
Hypertension (HTN)
Hypertension ,Pregnancy
Physical Activity
First Posted Date
2025-08-17
Last Posted Date
2025-08-17
Lead Sponsor
Northwestern University
Target Recruit Count
60
Registration Number
NCT07127731

Pediatricians Building Resilience Through Early Identification for Toddler Well-Being

Not Applicable
Not yet recruiting
Conditions
Mental Health
First Posted Date
2025-07-29
Last Posted Date
2025-07-29
Lead Sponsor
Northwestern University
Target Recruit Count
432
Registration Number
NCT07091240
Locations
🇺🇸

Nemours Children's Health, Wilmington, Delaware, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 269
  • Next

News

Northwestern University Develops Novel Nanostructure to Triple CRISPR Gene Editing Efficiency

Northwestern University researchers have developed lipid nanoparticle spherical nucleic acids (LNP-SNAs) that deliver CRISPR gene-editing tools up to three times more effectively than standard methods.

FDA-Approved Asthma Drug Zileuton Shows Promise in Preventing Food Allergy Reactions

Northwestern Medicine researchers discovered that Zileuton, an FDA-approved asthma drug, nearly eliminated life-threatening allergic reactions in mice by blocking a previously unknown pathway involving the DPEP1 gene.

Nature Study Validates LIXTE's PP2A Inhibitor LB-100 for Enhanced Cancer Immunotherapy

A Nature study led by MD Anderson researchers found that ovarian cancer patients with PPP2R1A mutations had significantly better overall survival when treated with immune checkpoint blockade therapy.

Prometheus Laboratories Expands Precision-Guided Dosing Platform with New Tests for IBD Biologics

Prometheus Laboratories launched PredictrPK VDZ and PredictrPK UST, precision-guided dosing tests for vedolizumab and ustekinumab in IBD patients, expanding their platform to cover four major biologics.

TRUST Trial Shows Primary Surgery Improves Progression-Free Survival in Advanced Ovarian Cancer Despite Missing Overall Survival Endpoint

The TRUST trial, the first phase III randomized study comparing surgical timing in advanced ovarian cancer, demonstrated statistically significant improvement in progression-free survival with primary cytoreductive surgery versus interval surgery (22.1 vs 19.7 months, HR=0.80, P=.018).

FDA Expands MenQuadfi Meningococcal Vaccine Approval to Include Infants as Young as 6 Weeks

The FDA approved an expanded indication for Sanofi's MenQuadfi meningococcal vaccine to include children aged 6 weeks to 23 months, making it the only MenACWY vaccine with no upper age limit.

Breakthrough Wireless Device Enables Remote Activation of Light-Sensitive Drugs for Pain Management

Scientists have developed the first wireless device capable of remotely activating photoactivable drugs, demonstrating effective pain management using photolabile morphine without typical opioid side effects.

Pneumonia Antibiotic Piperacillin Shows Promise as Targeted Lyme Disease Treatment at 100-Fold Lower Doses

Northwestern University researchers screened nearly 500 FDA-approved compounds and identified piperacillin as a potentially more effective Lyme disease treatment than current standard doxycycline therapy.

Grove Biopharma Secures $30M Funding, Expands to New R&D Facility in Chicago's Fulton Market

Grove Biopharma, a Northwestern University spinout developing therapies for intracellular disease targets, has secured $30 million in Series A financing to fuel its expansion and research initiatives.

ALS Drug NU-9 Shows Promising Results for Alzheimer's Disease in Animal Study

Northwestern University researchers found that NU-9, an experimental drug approved for ALS clinical trials, effectively reduces toxic protein buildup in Alzheimer's disease animal models.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.